Novo Nordisk A/S - Share repurchase programme
As part of the execution of Novo Nordisk's current DKK 17.5 billion
share repurchase programme expected to be finalised before the end of
2009, a repurchase programme is initiated today in accordance with
the provisions of the European Commission's regulation no 2273/2003
of 22 December 2003 (Safe Harbour regulation).
For that purpose Novo Nordisk has appointed J. P. Morgan Securities
Ltd. as lead manager to independently and without influence from Novo
Nordisk execute the programme. The purpose of the programme is
reduction of the company's share capital. Under the agreement, J. P.
Morgan Securities Ltd. will repurchase shares on behalf of Novo
Nordisk for an amount of up to DKK 1.7 billion during the trading
period starting today and ending on 19 December 2008. A maximum of
177,940 shares can be bought during one single trading day, equal to
15% of the average daily trading volume of Novo Nordisk B shares on
the OMX Nordic Exchange Copenhagen during the month of July 2008, and
a maximum of 16,192,540 shares in total can be bought during the
trading period. At least once every seven trading days, Novo Nordisk
will issue an announcement in respect of the transactions made under
the repurchase programme.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com
Company Announcement no 52 / 2008